Botswana CASCADE Clinical Trials Site

博茨瓦纳 CASCADE 临床试验现场

基本信息

批准号：
10544424
负责人：
Scott Dryden-Peterson
金额：
$ 25.78万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-05 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10544424
关键词：
AIDS clinical trial group AIDS related cancer Ablation Acquired Immunodeficiency Syndrome Africa African Area Botswana COVID-19 Prevention Network Caring Cause of Death Cervical Cervical dysplasia Cessation of life Clinical Research Clinical Trials Clinical Trials Network Clinical Trials Unit Collaborations Communities Community Health Education Consumption Country Cryptococcosis Data Devices Dysplasia Early Diagnosis Early treatment Economic Factors Effectiveness Enrollment Ethics Ethnic Origin Evaluation Female Adolescents Geography HIV HIV diagnosis Health Services Accessibility Health system High Prevalence Human Papilloma Virus Vaccination Human Papillomavirus Immunotherapy Impairment Improve Access Income Institutes International International Agencies International Maternal Pediatric Adolescent AIDS Clinical Trials Laboratories Language Lesion Malignant Neoplasms Malignant neoplasm of cervix uteri Mentors Observational Study Oncology Outcome Participant Patient Recruitments Patient risk Patients Performance Persons Population Prevalence Prevention Preventive service Protocols documentation Quality Control Relapse Research Research Personnel Resources Sampling Site Southern Africa Target Populations Techniques Technology Time Training Treatment Effectiveness Tuberculosis United States National Institutes of Health Universal Coverage Vaccines Viral Woman aged antenatal care antiretroviral therapy breast cancer diagnosis cancer diagnosis cancer invasiveness cancer prevention cancer therapy clinical research site cohort community engagement comparative trial data management data quality effectiveness evaluation experience improved innovation mortality new technology novel pragmatic trial premalignant prevent programs prospective quality assurance randomized trial research study screening screening program treatment optimization treatment program uptake

项目摘要

Project Summary / Abstract Successful HIV treatment programs in Botswana and elsewhere in southern Africa have led to dramatic reductions in mortality from tuberculosis, cryptococcosis, and other non-cancer AIDS deaths. However, cancer deaths have not decreased, and cervical cancer now is the leading cause of death for women living with HIV in the region. Cervical cancer is preventable with early detection and treatment of precancerous lesions but challenges of limited access to initial screening, poor performance of initial screening technologies, high prevalence of cervical precancers, and persistent or relapsed dysplasia following therapy impair the impact of programs for women living with HIV. Working to develop strategies to these challenges, we will establish the Botswana CASCADE Clinical Trials Site at BHP that will participate in and contribute to the following high- impact areas of research: 1) Enhancing cervical precancer screening uptake through patient and context relevant approaches, including HPV self-sampling, non-clinical screening venues, and screening during antenatal care; 2) Strategies and novel technologies to improve management of positive HPV initial screening maximize prevention of invasive cancer while minimizing patient risk and consumption of health system resources; 3) Improving precancer treatment access, treatment completion, and outcomes; and 4) Optimizing treatment approaches to cervical precancers including comparative trials of ablation techniques, intervals of repeat evaluation, and vaccines or other immunologic therapies. The Botswana CASCADE Clinical Trials Site will contribute to conducting high-quality clinical research studies, provide context-relevant input on developing trial concepts, understand disparity in access by geography, economic factors, and language/ethnicity, and continue to develop local research capacity through mentoring and training.

项目概要/摘要博茨瓦纳和南部非洲其他地区成功的艾滋病毒治疗计划带来了巨大的成功降低结核病、隐球菌病和其他非癌症艾滋病死亡的死亡率。然而，癌症死亡人数并没有减少，宫颈癌现在是感染艾滋病毒的妇女的首要死因。该地区。宫颈癌是可以通过早期发现和治疗癌前病变来预防的，但是初始筛选机会有限、初始筛选技术性能差、高宫颈癌前病变的患病率以及治疗后持续或复发的不典型增生会损害宫颈癌的影响针对感染艾滋病毒的妇女的计划。致力于制定应对这些挑战的战略，我们将建立位于必和必拓的博茨瓦纳 CASCADE 临床试验站点将参与并为以下高端项目做出贡献：研究的影响领域： 1) 通过患者和背景提高宫颈癌前筛查的采用率相关方法，包括HPV自我采样、非临床筛查场所以及期间筛查产前护理； 2) 改善HPV阳性初筛管理的策略和新技术最大限度地预防侵袭性癌症，同时最大限度地减少患者风险和卫生系统的消耗资源; 3) 改善癌前治疗的可及性、治疗的完成度和结果； 4) 优化宫颈癌前病变的治疗方法，包括消融技术的比较试验、治疗间隔重复评估、疫苗或其他免疫疗法。博茨瓦纳 CASCADE 临床试验网站将有助于开展高质量的临床研究，提供与背景相关的投入制定试验概念，了解地理、经济因素和语言/种族，并通过指导和培训继续发展当地的研究能力。